-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Pharmaceutical Guanlan
Jacos Pharmaceuticals recently announced that its research project, the KRAS G12C inhibitor JAB-21822, was approved for clinical use in China on May 27 following its recent clinical approval in the United States.
KRAS is one of the most frequently mutated oncogenes in human cancers.
Just today (May 29), the U.
JAB-21822 is a class 1 small molecule anti-tumor drug independently developed by Jacos Pharmaceuticals.
The press release pointed out that Jacosi Pharmaceuticals is committed to overcoming non-drugable targets.
Note: The original text has been deleted
Reference materials:
Reference materials:[1] GAX KRAS G12C inhibitor IND approved in China will start a Sino-US multi-center clinical trial.
[1] GAX KRAS G12C inhibitor IND approved in China will start a Sino-US multi-center clinical trial.
[2] The clinical trial application for the new drug of GKRAS KRAS G12C inhibitor was approved in the United States.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.